MANE

As of 2026-09-10, MANE scores 46out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. MANE trades at $99.67, within its fair-value band.

MANE scores 46 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 46. Its strongest factor is momentum at 59 (solid), where price trend and relative strength are working in its favor, followed by value at 50. The weakest is sentiment at 21, where sentiment signals are working against it. Among Healthcare stocks it ranks in roughly the top 39% of the Healthcare names the model scores.

On valuation, MANE is priced around the middle of its recent range. The blended composite before the macro overlay was 47. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on MANE, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where MANE sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for MANE runs $62.40–$129.61. Current price $99.67 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.